Vivostat, a company based in Scandinavia’s Medicon Valley, has developed and patented a new biotechnological process for the preparation of an autologous fibrin sealant used in cardiac, thoracic and orthopaedic surgery.
Vivostat is the only fully-closed and autonomous system [DM3] that can produce fibrin sealant and platelet-rich fibrin (PRF) directly from the patient’s blood. A blood sample is taken and processed to obtain one of the two aforementioned products, which is then applied to the patient in various medical fields, including general and thoracic surgery, difficult wounds and diabetic foot.
Vivostat boasts unrivalled adhesion, elasticity and biocompatibility properties, while the high regenerative capacity of the tissue to which PRF is applied is second to none.
ab medica s.p.a.
via J.F. Kennedy 10/12 20023 Cerro Maggiore (MI)
Phone +39 02.93305.1 Fax +39 02.93305.400 abmedica@abmedica.it
business register no. 08862820969
paid-up share capital € 10.000.000
ab medica s.p.a. via J.F. Kennedy 10/12 20023 Cerro Maggiore (MI) Phone +39 02.93305.1 Fax +39 02.93305.400 abmedica@abmedica.it business register no. 08862820969 paid-up share capital € 10.000.000
SOLUZIONI
SOLUTIONS